Kala Pharmaceuticals Inc. (NASDAQ:KALA) shares traded 99.04% higher at $24.84 on Wall Street last session.
In accordance with the data, 3 analysts cover Kala Pharmaceuticals Inc. (NASDAQ:KALA). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $47.00 and a low of $12.00, we find $37.00. Given the previous closing price of $12.48, this indicates a potential upside of 196.47 percent. KALA stock price is now 314.22% away from the 50-day moving average and 11.68% away from the 200-day moving average. The market capitalization of the company currently stands at $35.77M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 0 analysts and a buy by 3. Brokers who have rated the stock have averaged $32.00 as their price target over the next twelve months.
, while ‘Jefferies’ rates the stock as ‘Hold’.
In other news, Reumuth Mary, CHIEF FINANCIAL OFFICER sold 194 shares of the company’s stock on Oct 26. The stock was sold for $1,263 at an average price of $6.51. Upon completion of the transaction, the CHIEF FINANCIAL OFFICER now directly owns 2,418 shares in the company, valued at $60063.12. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 26, SEE REMARKS Bazemore Todd sold 214 shares of the business’s stock. A total of $1,393 was realized by selling the stock at an average price of $6.51. This leaves the insider owning 2,097 shares of the company worth $52089.48. Insiders disposed of 3,878,037 shares of company stock worth roughly $96.33 million over the past 1 year. A total of 1.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KALA stock. A new stake in Kala Pharmaceuticals Inc. shares was purchased by MAN GROUP PLC during the first quarter worth $23,000. TOWER RESEARCH CAPITAL LLC (TRC) invested $19,000 in shares of KALA during the first quarter. In the first quarter, GSB WEALTH MANAGEMENT, LLC acquired a new stake in Kala Pharmaceuticals Inc. valued at approximately $10,000. KEYSTONE WEALTH PARTNERS acquired a new stake in KALA for approximately $7,000. AMALGAMATED FINANCIAL CORP. purchased a new stake in KALA valued at around $4,000 in the second quarter. In total, there are 95 active investors with 15.90% ownership of the company’s stock.
Kala Pharmaceuticals Inc. (NASDAQ: KALA) opened at $16.13 on Thursday. During the past 12 months, Kala Pharmaceuticals Inc. has had a low of $3.54 and a high of $97.00. The fifty day moving average price for KALA is $6.00 and a two-hundred day moving average price translates $22.24 for the stock.
The latest earnings results from Kala Pharmaceuticals Inc. (NASDAQ: KALA) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$19, beating analysts’ expectations of -$21.75 by 2.75. This compares to -$21.42 EPS in the same period last year. The company reported revenue of $0.42 million for the quarter, compared to $3.07 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -86.31 percent. For the current quarter, analysts expect KALA to generate $41.67M in revenue.
Kala Pharmaceuticals Inc.(KALA) Company Profile
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company’s product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
